PHARMACOLOGICAL MODULATION OF REDOX HOMEOSTASIS: MECHANISMS AND THERAPEUTIC IMPLICATIONS IN HUMAN DISEASES

Nandhini Devi M*[1,7], Manikandan V[2,7], Boopathi T[3,7], Sabarinathan A[4,7], Nandhini S[5,7], Poojaa Shri N[6,7]

[1]Department of Pharmacology, Karpagam College of Pharmacy, Coimbatore, India.

[2]Department of Pharmaceutics, Karpagam College of Pharmacy, Coimbatore, India.

[3]Department of Pharmacology, Karpagam College of Pharmacy, Coimbatore, India.

[4]Department of Pharmacognosy, Karpagam College of Pharmacy, Coimbatore, India.

[5]Department of Pharmacy Practice, Karpagam College of Pharmacy, Coimbatore, India.

[6]Department of Pharmacy Practice, Karpagam College of Pharmacy, Coimbatore, India.

[7]The TamilNadu Dr.MGR Medical University, Chennai- 600032, Tamilnadu India.

Corresponding Author:

Ms. Nandhini Devi M,

Department of Pharmacology,

Karpagam College of Pharmacy,

Coimbatore – 641032. Tamilnadu, India.

Abstract

Redox homeostasis is the equilibrium that exists between the an aerobic generation of oxygen and nitrogen species and the body's built-in defense system that acts as protecting shields (antioxidants). This balance is crucial in the preservation of the integrity of the cell and the maintenance of physiological activities and any distorted balance would mean stress, in particular the oxidative stress, which is defined as the detrimental overabundance of reactive oxygen and nitrogen species (RONS) and the undersupply of cellular antioxidants which is a lie. It is now well understood that oxidative stress is a core element in the beginning and the development of an array of ailments such as the neurodegenerative conditions (Alzheimer's and Parkinson's) stress-related disorders, heart illness, malignant tumors and the metabolic disease of diabetes and obesity. Also, the last few years, the sub-branch of oxidative signalling have gained much interest as a potential therapeutic target, signalling that restore the redox balance by neutralization of the reactive oxygen species (ROS) as well as targeted redox-sensitive molecular pathway modulation. This review takes a close look at how redox imbalance contributes to disease development and checks out the current and upcoming drug

strategies that aim to fix oxidative stress. It really highlights the potential of therapies that target important pathways, like activating nuclear factor erythroid 2–related factor 2 (NRF2), stopping ferroptosis (which is a type of cell death driven by redox), and using drug delivery systems that respond to redox changes. Altogether, these strategies offer a fresh perspective in redox pharmacology, with significant implications for treating and preventing complex human diseases.

Keywords: Redox Homeostasis, Oxidative Stress, Antioxidants, NRF2, ROS, Ferroptosis, Mitochondria, Pharmacological Modulation

1. Introduction

Cells continuously undergo metabolic processes that produce reactive oxygen (ROS) and nitrogen (RNS) species, primarily from mitochondrial oxidative phosphorylation, and enzymatic processes catalyzed by NADPH oxidases and nitric oxide synthases. When produced under homeostatic conditions, these reactive species have important biological roles for regulating intracellular signaling cascades, and modulating immune function and programmed cell death (apoptosis). Ultimately, in a homeostatic cellular state, redox signaling has beneficial effects to cellular homeostasis and adaptation to stress.

However, when production of ROS and RNS goes beyond the ability of biological antioxidant mechanisms (i.e, superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), and non-enzymatic antioxidants includes glutathione (GSH), vitamins C and E), to mitigate redox signals, oxidative stress occurs. When the redox system becomes unbalanced, oxidative damage occurs that leads to oxidation of DNA, proteins, and lipids, which in turn leads to structural and functional changes at the cellular level. Finally, with continuing insult by oxidative species, ultimately the cellular injury will lead to dysfunction of the organ and persist in the development and progression of chronic and degenerative diseases.

It is widely recognized that redox dysregulation occurs in a variety of the most debilitating human diseases including neurodegenerative diseases, cardiovascular disease, cancer, and metabolic syndromes, prompting a comprehensive investigation of pharmacological approaches to targeting oxidative stress. Such approaches include, but are not restricted to: boosting cellular antioxidant capacity, scavenging free-radicals, and more sophisticated approaches such as selectively altering the redox vulnerability of cancer cells or modulating redox-sensitive signaling pathways.

Table 1. Summary of Key Diseases Linked to Oxidative Stress Antioxidant

Disease	Mechanistic Role of ROS/RNS	Major Consequences
Alzheimer's disease	Aβ aggregation, tau hyperphosphorylation	Neurodegeneration, memory loss
Parkinson's disease	Mitochondrial dysfunction, dopaminergic toxicity	Motor dysfunction, neuro inflammation
Atherosclerosis	LDL oxidation, eNOS uncoupling	Endothelial dysfunction, plaque formation
Type 2 diabetes	β-cell apoptosis, insulin resistance	Hyperglycemia, metabolic dysregulation
Cancer	DNA damage, ROS-driven signalling	Proliferation, metastasis, therapy resistance

2. Pathophysiological Role of Redox Imbalance

The homeostatic regulation of redox balance is vital for cellular and systemic health. When this balance is disrupted due to excessive ROS/RNS production or impaired antioxidant responses it contributes directly to the pathogenesis of a wide spectrum of diseases. The deleterious effects of oxidative stress are highly context-dependent, influencing disease progression through tissue-specific molecular mechanisms. Below, we explore the role of redox imbalance in key human disorders.

2.1 Neurodegenerative Diseases

Neurodegenerative disorders such as Alzheimer disease (AD), Parkinson disease (PD), and amyotrophic lateral sclerosis (ALS) are characterized by different forms of progressive neuronal loss, along with cognitive or motor decline. There are multiple lines of evidence highlighting the contribution of oxidative stress to the pathophysiology of these disorders. In AD for instance, it is believed that elevated ROS levels contribute to the aggregation of β-amyloid (Aβ) plaques and hyperphosphorylated tau protein, both of which adversely

contribute to synaptic dysfunction and neuronal loss that ultimately results in memory deficits and cognitive decline[1]. Similarly, in PD, dysfunction of mitochondrial complex I results in elevated ROS production and affects primarily dopaminergic neurons in the substantia nigra and leads to the motor deficits associated with the disease. Furthermore, dysfunction of redox homeostasis exacerbates mitochondrial disruption and attenuation of calcium signalling along with microglia-mediated neuroinflammatory processes which further promote disease progression. There is ongoing interest in developing pharmacological approaches to target mitochondrial oxidative stress and also increase neuronal antioxidant capacity as a neuroprotective strategy [2].

2.2 Cardiovascular Diseases

The cardiovascular system is particularly exposed to oxidative damage because of high oxygen demands and extensive vascular systems. In cardiovascular diseases (CVDs) such as hypertension, atherosclerosis, and heart failure, oxidative stress can initiate and perpetuate pathological processes. Major enzymatic sources of reactive oxygen species (ROS) in vascular tissues include NADPH oxidases (NOX), uncoupled endothelial nitric oxide synthase (eNOS), and xanthine oxidase. ROS such as superoxide and other radicals lead to degradation of nitric oxide (NO), a potent vasodilator, thereby decreasing endothelial function and contributing to vasoconstriction, inflammation, and thrombosis [3]. In addition, ROS-induced oxidative modification of low-density lipoprotein (LDL) promotes foam cell formation and contributing to atherogenesis. Antioxidant therapy, which can either scavenge ROS or enhance NO bioavailability, has shown promise targeting oxidative processes in preclinical studies. However, HUMAN translation has proven problematic.

2.3 Cancer

Cancer cells have a unique relation to reactive oxygen species (ROS), presenting a unique paradox. First, oncogenic transformation and fast proliferation result in increased metabolic activity, generating increased amounts of ROS. Increased levels of ROS can activate protective/pro-survival signalling pathways (e.g., PI3K/AKT and NF-κB) that facilitate tumor initiation and progression. In the opposite sense, increased ROS production can push a cell's capacity for ROS tolerance beyond what it can tolerate, especially in cases of oxidative stress, resulting in reactive oxygen species-induced damage to DNA, cell cycle arrest, and apoptosis [4].

This paradox creates a therapeutic opportunity to target cancer cells by further enhancing oxidative stress and/or inhibiting the antioxidant defence systems (e.g., glutathione, thioredoxin and NRF2 pathways) that cancer cells rely on, while sparing normal cells. Beyond promoting or preventing cell death, redox status can modify angiogenesis, metastasis, and resistance (including resistance to chemotherapy) to cancer therapies and pharmacology, framing redox modulation as an important therapeutic approach within cancer pharmacology.

2.4 Metabolic and Inflammatory Diseases

Oxidative stress is closely correlated with various metabolic syndromes including obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Chronic hyperglycemia, as well as increased concentrations of free fatty acids, raise the production of mitochondrial superoxide, which may subsequently have detrimental effects on insulin signalling and glucose uptake. Oxidative processes also damage pancreatic β-cells, inducing dysfunction and apoptosis thereby worsening insulin deficiency [5].

In chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, reactive oxygen species (ROS) can induce tissue destruction by stimulating numerous pro-inflammatory cytokines (e.g., TNF-α, IL-6) as well as matrix metalloproteinase production. This potentiation of inflammatory responses leads to joint or mucosal damage[6]. Altering oxidative pathways in these disorders may serve to restore certain aspects of metabolic and immune homeostasis.

Table 2. Antioxidant-Based Therapeutic Agents

Agent	Mechanism	Therapeutic Use
NAC	GSH replenishment, ROS scavenger	Respiratory diseases, neuroprotection
Vitamin C	Aqueous ROS scavenger, regenerates Vit E	Antioxidant supplement, CVD
Vitamin E	Lipid peroxidation inhibitor	CVD, neurodegeneration
Edaravone	Hydroxyl radical scavenger, BBB penetration	Stroke, ALS
MitoQ, SkQ1	Mitochondrial ROS scavengers	Neuro/cardioprotection
Elamipretide	Stabilizes mitochondrial	Heart failure, mitochondrial

	membrane	myopathy

3. Pharmacological Modulation Strategies

The redox regulatory network is a pillar of cellular physiology, and its dysregulation contributes to a wide range of disease states. From an intervention standpoint, the complexity is a rich resource for selective targeting of therapeutic interventions. Interventions aimed at redox modulation can be divided into four categories:

(i) Classical and new antioxidant therapies

(ii) Pro-oxidant approaches, which selectively target cancer cells

(iii) Agents that exploit redox-sensitive signalling pathways through the NRF2 pathway in particular

(iv) Mitochondrial redox modulators, with the specific intent to intercept reactive oxygen species (ROS) production at the site of production.

Table 3. Pro-oxidant and NRF2-Modulating Therapies

Class	Drug	Mechanism	Clinical Indication
Pro-oxidants	Arsenic trioxide	ROS generation, mitochondrial depolarization	Acute promyelocytic leukemia
Pro-oxidants	β-Lapachone	ROS via NQO1 redox cycling	NQO1+ tumors
Pro-oxidants	Doxorubicin	DNA intercalation, ROS generation	Broad-spectrum anticancer (with dexrazoxane)
NRF2 activators	Dimethyl fumarate	KEAP1 alkylation → NRF2 activation	Multiple sclerosis, psoriasis
NRF2 activators	Bardoxolone methyl	NRF2 activation + NF-κB inhibition	CKD, anticancer (experimental)

3.1 Antioxidant Therapies

Antioxidants act by neutralizing excess reactive oxygen and nitrogen species, thereby returning the cell's redox state to balance. Both endogenous and synthetic antioxidants have been tested for therapeutic use in multiple disease contexts.

3.1.1 N-Acetylcysteine (NAC)

N-Acetylcysteine is a thiol-based antioxidant used for its ability to replenish intracellular glutathione (GSH), a principal redox buffer. In addition to its traditional use for acetaminophen toxicity, NAC has been demonstrated to be beneficial for patients with chronic respiratory diseases, neuropsychiatric disorders (e.g., schizophrenia and bipolar disorder), and viral infections like COVID-19. The reason for NAC's versatility is that it scavenges ROS directly, and it may inhibit the production of proinflammatory cytokines. In the context of neurology, NAC is currently under investigation in a clinical trial for its potentially neuroprotective properties in patients with Parkinson's Disease and autism spectrum disorder.

3.1.2 Vitamins C and E

Both ascorbic acid (vitamin C) and α-tocopherol (vitamin E) are fundamental antioxidants to dietary supplements. Vitamin C acts in aqueous compartments to scavenge superoxide and hydroxyl radicals and recycle other antioxidants, including vitamin E. Vitamin E acts in lipid membranes to protect polyunsaturated fatty acids from peroxidation. Although large-scale clinical trials produced mixed outcomes, evidence is accumulating for their role in patients with nutritional deficiencies, chronic oxidative stress, or individual-level genotypic risks for antioxidant dysfunction[7].

3.1.3 Edaravone

Edaravone is a generation of synthetic antioxidant with selective action against hydroxyl radicals. Edaravone can be used in Japan for acute ischemic strokes and amyotrophic lateral sclerosis (ALS) disorders. Edaravone acts by mitigating neuronal oxidative injury, preserving the blood-brain barrier, and regulating neuroinflammation. Edaravone has rapid actions and readily crosses the blood-brain barrier, making it an exciting choice for use in acute neurovascular syndromes and chronic neurodegenerative conditions.

3.2 Redox-Based Pro-Oxidant Strategies in Cancer

Excessive reactive oxygen species (ROS) are certainly cytotoxic, but in cancer, intermediaries of controlled oxidative stress may be fundamental in the proliferation and survival of cancer cells. In this paradox, it also lends itself to a therapeutic window where pro-oxidant therapies can push cancer cells beyond their tolerable high levels of oxidative capacity, leading to death.

3.2.1 Arsenic Trioxide

Arsenic trioxide is a paradigmatic pro-oxidant for treating acute promyelocytic leukemia (APL). It brings about mitochondrial membrane depolarization and promotes apoptosis, invoking oxidative stress, to promote mitochondrial dysfunction intrinsic to leukemic cells. The mechanism is redox-dependent but closely regulated to prevent organismal toxicity[8].

3.2.2 β-Lapachone

β-Lapachone is a quinone that covalently modifies and targets tumors overexpressing NAD(P)H:quinone oxidoreductase 1 (NQO1). When delivered, it undergoes futile redox cycling (i.e. consumes and regenerates NADH) in NQO1 abundant cells and leads to the generation of high levels of ROS, causing biochemistry alterations producing DNA damage leading to cancer-specific cytotoxicity. Because of its tumor specificity, β-lapachone presents as an attractive candidate for redox-guided cancer therapies.

3.2.3 Doxorubicin

Doxorubicin is arguably one of the most used, if not one of the mainline chemotherapeutic, drugs in children's oncology, and it works by intercalating into DNA and generating ROS. However, its use is limited because of the dose-dependent cardiotoxicity primarily exemplified by oxidative damage to cardiomyocyte mitochondria. Doxorubicin is sometimes co-administered with a cardioprotective agent, dexrazoxane, which chelates.

3.3 NRF2 Signaling Modulators

Nuclear factor erythroid 2-related factor 2 (NRF2) is the essential transcription factor for endogenous antioxidant defense. Under homeostatic basal levels, NRF2 cytoplasm my u

chain and degrade by proteasome through the action of Kelch-like ECH-associated protein 1 (KEAP1). When exposed to oxidated stress or toxins, NRF2 is stabilized and translocates to the nucleus where it activates genes involving cytoprotective genes, including hemoxygenase-1 (HO-1), NADPH quinone oxidoreductase 1 (NQO1) and Glutamate-Cysteine Ligase Modifier (GCLM)[9].

3.3.1 Dimethyl fumarate (DMF)

Dimethyl fumarate (DMF) is an FDA-approved treatment for relapsing-remitting multiple sclerosis is approved and is undergoing clinical investigations or psoriasis because DMF is a specific KEAP1 alkylator, leading to the activation of NRF2. In addition to inducing antioxidant gene expression, DMF inhibits the evidence for increased pro-inflammatory NF-κB pathways. Accordingly, DMF demonstrated both immunomodulatory and neuroprotective effects and long-term readout studies demonstrating decreased disease progression. Consequently, modulation of NRF2 for the treatment of inflammatory neurodegeneration leaves open the possibility for dual-action treatment options.

3.3.2 Bardoxolone methyl

Bardoxolone methyl is a triterpenoid is a very potent synthetic and robust NRF2 activator. In addition, bardoxolone methyl has demonstrated inhibition of NF-κB signaling pathways. Bardoxolone methyl has demonstrated a number of direct renoprotective and anti-cancer benefits but as with all drugs the competition is a considerable barrier in clinical development due to cardiovascular safety indications. Bardoxolone methyl serves as a template for generation of next-generation NRF2 activators that are structurally designed with the intent to improve selectivity and tolerability.

3.4 Mitochondria-Targeted Antioxidants

Given that mitochondria are both the primary source and victim of ROS, direct targeting of mitochondrial oxidative stress is emerging as a precision strategy to restore redox homeostasis without disrupting systemic redox signalling[10].

3.4.1 MitoQ and SkQ1

MitoQ and SkQ1 are pioneering compounds that conjugate antioxidant molecules to lipophilic triphenylphosphonium (TPP+) cations, facilitating selective mitochondrial uptake. MitoQ, a ubiquinone derivative, and SkQ1, a plastoquinone analog, effectively scavenge

mitochondrial ROS and have shown protective effects in preclinical models of neurodegeneration, cardiovascular dysfunction, and ischemia-reperfusion injury. Their targeted delivery significantly enhances efficacy while minimizing off-target effects.

3.4.2 Elamipretide (SS-31)

Elamipretide is a small mitochondria-targeting tetrapeptide that binds cardiolipin, stabilizing the inner mitochondrial membrane and enhancing electron transport chain efficiency. It has demonstrated therapeutic promise in mitochondrial myopathies, heart failure, and age-related macular degeneration by reducing oxidative stress and preserving mitochondrial bioenergetics. Its ongoing clinical development highlights the translational relevance of mitochondrial-targeted antioxidants in oxidative pathologies.

4. Emerging Trends and Novel Agents

The ongoing exploration of redox biology has catalyzed the development of innovative therapeutic strategies that go beyond conventional antioxidant supplementation. Recent discoveries emphasize not only the modulation of reactive oxygen species (ROS) but also the fine-tuning of redox-sensitive cellular death pathways, targeted drug delivery mechanisms, and clinically viable compounds that restore redox equilibrium. This section delves into three promising avenues ferroptosis inhibition, redox-guided drug delivery, and redox-active clinical candidates that exemplify the future of redox-targeted pharmacotherapy[11].

4.1 Ferroptosis Inhibitors

Ferroptosis represents a unique, non-apoptotic form of regulated cell death driven by iron-dependent accumulation of lipid peroxides. Unlike traditional necrotic or apoptotic pathways, ferroptosis is intimately tied to the disruption of cellular antioxidant defenses—particularly glutathione peroxidase 4 (GPX4) activity—and an excess of intracellular iron and polyunsaturated fatty acids. This mode of cell death has been implicated in a variety of pathological contexts, including ischemia-reperfusion injury, neurodegeneration, and acute kidney injury[12].

Pharmacological inhibition of ferroptosis has emerged as a viable protective strategy. Small molecules such as **ferrostatin-1** and **liproxstatin-1** are potent ferroptosis suppressors, functioning by neutralizing lipid ROS and preserving membrane integrity. These agents have shown efficacy in preclinical models of stroke, traumatic brain injury, and cardiac ischemia.

Furthermore, certain natural flavonoids, such as baicalein and quercetin, exhibit intrinsic ferroptosis-inhibitory effects, highlighting their therapeutic potential in chronic neuroinflammatory and degenerative disorders[13].

4.2 Redox-Guided Drug Delivery

An exciting frontier in redox pharmacology lies in the development of ROS-responsive drug delivery systems**.** These nanotechnology-based platforms exploit the elevated oxidative stress microenvironment of diseased tissues—especially tumors and inflamed sites—to trigger site-specific drug release.

Examples include polymeric nanoparticles**,** liposomes, and micelles that are engineered with redox-sensitive linkers (e.g., disulfide bonds or thioketal linkages). Upon encountering high ROS levels, these linkers undergo cleavage, leading to controlled drug liberation precisely at the pathological site. This approach minimizes systemic toxicity and enhances the therapeutic index of anticancer and anti-inflammatory drugs[14] .

Similarly, redox-activated prodrugs—inactive molecules that become pharmacologically active upon ROS exposure—are gaining attention. These platforms allow for the selective cytotoxicity of chemotherapeutics within tumor cells while sparing healthy tissues, offering a strategic advantage in oncology[15].

4.3 Clinical-Stage Compounds

Several redox-modulating compounds have progressed from bench to bedside and are currently under clinical investigation for various oxidative stress–related conditions. One of the most notable is sonlicromanol (KH-176), a redox-active molecule that targets the thioredoxin/peroxiredoxin system, a critical axis in mitochondrial redox regulation. KH-176 has demonstrated promise in early-phase clinical trials for mitochondrial disorders and is being evaluated for post-COVID syndrome, a condition marked by persistent oxidative and inflammatory stress[16].

In parallel, natural polyphenols like resveratrol, curcumin, and epigallocatechin gallate (EGCG) continue to be studied for their pleiotropic antioxidant, anti-inflammatory, and mitochondria-protective effects. Although their bioavailability and pharmacokinetics remain challenges, advances in formulation science—such as nanoencapsulation and liposomal delivery—are improving their translational potential in managing cardiovascular, neurodegenerative, and metabolic diseases[17].

5. Challenges and Future Perspectives

Despite promising advances in redox-based therapeutics, several critical challenges must be addressed to fully harness the potential of redox modulation in clinical practice. The complexity of redox biology demands a nuanced approach—one that balances efficacy, safety, and precision in targeting oxidative stress-related pathologies. This section outlines the key obstacles and prospective directions in this evolving field.

Table 4. Emerging and Experimental Redox Modulators

Category	Example	Key Target	Potential Indications
Ferroptosis inhibitors	Ferrostatin-1, Liproxstatin-1	Lipid ROS suppression	Stroke, AKI, neurodegeneration
Natural flavonoids	Baicalein, Quercetin	Ferroptosis suppression	Neuroinflammation, neurodegeneration
ROS-responsive DDS	Disulfide/micelle nanoparticles	ROS-triggered drug release	Cancer, inflammatory disorders
Clinical candidates	Sonlicromanol (KH-176)	Thioredoxin/peroxiredoxin system	Mitochondrial disorders, post-COVID
Polyphenols	Resveratrol, Curcumin, EGCG	Antioxidant + anti-inflammatory	Cardiometabolic and neurodegenerative diseases

5.1 The Duality of ROS: A Double-Edged Sword

Reactive oxygen species (ROS) have traditionally been viewed as deleterious byproducts of cellular metabolism. However, it is now well established that ROS also serve essential roles in cell signaling, immune defense, and tissue homeostasis. Basal ROS levels are critical for physiological functions such as cell proliferation, differentiation, autophagy, and angiogenesis. Therefore, the indiscriminate scavenging of ROS through excessive antioxidant supplementation can disrupt these fundamental processes and may even impair host defense mechanisms.

This duality highlights the need for fine-tuned modulation of redox states rather than complete suppression. The future of redox therapeutics lies in context-specific intervention—targeting pathological ROS overproduction while preserving physiological oxidative signaling[18].

5.2 Target Specificity and Tissue Selectivity

One of the foremost challenges in redox pharmacology is achieving target specificity. Redox imbalances are often localized within certain cell types, tissues, or subcellular compartments (e.g., mitochondria), while the surrounding tissues may maintain normal redox homeostasis. Current antioxidant therapies often lack the precision to selectively modulate oxidative stress at the disease site, leading to off-target effects or insufficient efficacy[19].

Future strategies must prioritize tissue-specific delivery mechanisms, such as ROS-activated nanocarriers, enzyme-responsive prodrugs, or organ-targeted formulations that respond to local redox cues. Advances in molecular imaging and redox sensors could also aid in mapping oxidative stress gradients, enabling real-time tracking and controlled intervention[20].

5.3 Absence of Consistent Biomarkers

A considerable barrier remains in accurately assessing oxidative stress *in vivo*. Most available methodologies are based upon indirect or non-specific markers, including malondialdehyde (MDA), 8-isoprostane or total antioxidant capacity, which does not reliably or specifically measure the redox state in various tissues or cellular compartments.

The need for reliable, specific, non-invasive biomarkers of oxidative stress is essential given the potential for biomarkers to better stratify patients, monitor therapy and customize treatment. Some theoretical candidates could include redox-sensitive transcription factors (e.g., Nrf2 activity), glutathione redox ratios (GSH/GSSG), or circulating microRNAs that may reflect oxidative-stress pathways[21].

5.4 Rational Combination Therapeutics

Oxidative stress in and of itself is not typically a sole driver of disease. Oxidative stress often co-exists with other pathophysiologies such as chronic inflammation, metabolic dysfunction, immune dysregulation or disruption and genomic instability. Therefore, the use of any redox-modulating therapy as monotherapy may not be a suitable therapeutic approach in a complex disease context.

A rapidly developing paradigm is in the rational combination of redox-targeted agents with other therapies, without concomitant cell or organ stress. For example, the combination of ROS-inducing chemotherapeutics with ferroptosis inhibitors maximize tumor cell death while limiting potential off-target toxicity. Similarly, redox modulators may also be combined with checkpoint blockade immunotherapy by limiting tumor-induced immunosuppression[22].

6. Conclusion

Redox homeostasis provides a foundational component for cellular viability, physiological signaling, and immune surveillence. Its precise nuances govern a diverse set of biological processes from gene expression, through metabolic regulation, apoptosis, and to tissue repair. Conversely, when redox status is disrupted via deleterious oxidation (due to increased reactive oxygen species (ROS) production) or inadequate antioxidant defense, redox dysregulation is driven to contribute to the pathogenesis of several diseases like cancers, neurodegeneration, cardiovascular diseases, and metabolic syndromes.The pharmacologic intervention of redox status is an emerging therapeutic strategy. This can be achieved through directed circumstances of antioxidant therapy, selective oxidative stress in malignant cells, or spatiotemporally controlled release of redox-sensitized nanocarriers, and provides great promise for improving disease outcomes with reduced systemic toxicity.

Importantly, the future of redox-based, precision therapy will not consist of a generalized notion of redox status, but a doctor-guided personalization of treatment that considers the conditions of the redox phenotype of the subject, tissue, or disease. Advances in redoxomics, systems biology, and imaging will be invaluable in identifying predictive biomarkers of redox status and in situ monitoring of treatment.

Furthermore, the coupling of redox modulation with combinatorial therapeutic modalities (e.g., immunotherapies, chemotherapeutics, and metabolic modulators) provides a unique opportunity to potentially synergize pathways and bypass resistance mechanisms. As we continue to map the redox framework, multi-modal approaches that consider redox balance as a modulator and target will reshape the treatment paradigm for a wide variety of human disease. In summary, redox pharmacology is uniquely positioned at the leading edge of translational innovation. With continued interdisciplinary research and clinical validation, the application of redox pharmacology will quickly become a mainstay in near-term next-generation precision medicine.

References

1. Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. *Nat Rev Neurosci*. 2019;20(3):148–160.
2. Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. *J Neurochem*. 2016;139 Suppl 1:216–231.
3. Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. *Circ Res*. 2017;120(4):713–735.
4. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nat Rev Drug Discov*. 2009;8(7):579–591.
5. Mateen S et al. Role of oxidative stress and antioxidant balance in rheumatoid arthritis. *Biomed Pharmacother*. 2016;81:239–246.
6. De Flora S et al. N-Acetylcysteine in the treatment of COVID-19: a systematic review. *Eur Rev Med Pharmacol Sci.* 2021;25(7):2742–2756.
7. Sesso HD et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA.* 2008;300(18):2123–2133.
8. Abe K et al. Edaravone improves functional recovery and reduces infarct size in rats with focal cerebral ischemia. *Stroke*. 2000;31(8):1930–1935.
9. Shen Z et al. Arsenic trioxide induces apoptosis in leukemia cells through a ROS-dependent pathway. *Blood.* 2004;104(3):1012–1020.
10. Bey EA et al. An NQO1 bioactivatable drug drives ROS-mediated cancer cell death. *Cancer Cell.* 2007;12(1):17–27.
11. Minotti G et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev*. 2004;56(2):185–229.
12. Linker RA et al. Fumaric acid esters – pharmacology and mode of action. *Curr Med Chem*. 2010;17(30):3243–3252.
13. Pergola PE et al. Effect of bardoxolone methyl on kidney function in patients with T2DM and stage 3b–4 CKD. *N Engl J Med.* 2011;365(4):327–336.
14. Smith RA et al. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. *Annu Rev Pharmacol Toxicol.* 2008;48:353–375.
15. Zhao K et al. A novel peptide protects mitochondrial function and reduces oxidative stress in ischemic hearts. *J Mol Cell Cardiol.* 2004;37(5):957–964.
16. Dixon SJ et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell.* 2012;149(5):1060–1072.
17. Meng H et al. Engineering the properties of metal-based nanotherapeutics for improved safety and efficacy. *Natl Sci Rev.* 2019;6(3):513–548.
18. Koopman WJ et al. KH176 Safeguards mitochondrial redox balance in mitochondrial disease patient fibroblasts. *Cell Metab.* 2017;26(4):788–800.
19. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. *Mol Cell*. 2012;48(2):158–167. https://doi.org/10.1016/j.molcel.2012.09.025

20. Chinta SJ, Andersen JK. Redox imbalance in Parkinson's disease. *Biochim Biophys Acta*. 2008;1780(11):1362–1367. https://doi.org/10.1016/j.bbagen.2008.01.005
21. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage *in vivo* and in cell culture: How should you do it and what do the results mean? *Br J Pharmacol*. 2004;142(2):231–255. https://doi.org/10.1038/sj.bjp.0705776
22. Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. *J Exp Med*. 2012;209(2):211–215. https://doi.org/10.1084/jem.20110947.